Endonovo Therapeutics, Inc. (ENDV)
USD 0.0
(14.29%)
USD 0.0
(14.29%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 140.24 Thousand | 135.35 Thousand | 73.1 Thousand | 165.79 Thousand | 310.16 Thousand | 83.26 Thousand |
| Cost of Revenue | 654.75 Thousand | 9990.00 | 14.98 Thousand | 65.36 Thousand | 93.38 Thousand | 12.93 Thousand |
| Gross Profit | -514.51 Thousand | 125.36 Thousand | 58.12 Thousand | 100.42 Thousand | 216.77 Thousand | 70.33 Thousand |
| Operating Expenses | 2.4 Million | 3.38 Million | 2.28 Million | 3.01 Million | 4.02 Million | 4.22 Million |
| Selling, General and Administrative Expenses | 2.4 Million | 2.74 Million | 1.63 Million | 2.35 Million | 3.22 Million | 4.24 Million |
| Research and Development Expenses | - | - | - | 3283.00 | 153.12 Thousand | 274.26 Thousand |
| Other Expenses | - | 3.38 Million | 2.28 Million | 3.01 Million | 4.02 Million | -12.93 Thousand |
| Cost and Expenses | 3.05 Million | 3.39 Million | 2.29 Million | 3.07 Million | 4.11 Million | 4.24 Million |
| Operating Income | -2.91 Million | -3.26 Million | -2.22 Million | -2.91 Million | -3.8 Million | -4.15 Million |
| Interest Expense | 1.28 Million | 1.32 Million | 941.56 Thousand | 2.08 Million | 6.09 Million | 5.19 Million |
| Income Tax Expense | - | 13.66 Million | 941.56 Thousand | 1.63 Million | 6.09 Million | 2.92 Million |
| Earnings before Tax | 6.92 Million | -18.47 Million | -3.1 Million | -395.58 Thousand | -17.31 Million | -6.43 Million |
| Net Income | 6.92 Million | -32.13 Million | -4.04 Million | -2.02 Million | -23.4 Million | -6.43 Million |
| Earnings Per Share Basic | 0.03 | -0.23 | -0.07 | -0.17 | -33.56 | -17.76 |
| Earnings Per Share Diluted | 0.01 | -0.23 | -0.07 | -0.17 | -33.56 | -17.76 |
| Weighted Average Shares Outstanding | 276.35 Million | 139.2 Million | 59.83 Million | 12.21 Million | 697.3 Thousand | 362.46 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 1.35 Billion | 139.2 Million | 59.83 Million | 12.21 Million | 697.3 Thousand | 362.46 Thousand |
| Gross Margin | -3.67 | 0.93 | 0.80 | 0.61 | 0.70 | 0.84 |
| EBIT Margin | 63.13 | -21.00 | -21.59 | -16.36 | -10.18 | -77.22 |
| Profit Margin | 49.38 | -237.44 | -55.35 | -12.22 | -75.46 | -77.30 |
| EBITDA | 8.85 Million | -16.5 Million | -1.51 Million | -2.26 Million | -10.57 Million | -588.5 Thousand |
| Earnings Before Tax Margin | -20.82 | -24.12 | -30.46 | -17.56 | -12.28 | -49.95 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 1661.00 | 8382.00 | 140.24 Thousand | 5982.00 | 1520.00 | 45.2 Thousand |
| Cost of Revenue | 163.64 Thousand | 166.52 Thousand | 654.75 Thousand | 164.74 Thousand | 827.00 | 161.72 Thousand |
| Gross Profit | -161.98 Thousand | -158.13 Thousand | -514.51 Thousand | -158.76 Thousand | 693.00 | -116.52 Thousand |
| Operating Expenses | 249.97 Thousand | 241.89 Thousand | 2.4 Million | 627.28 Thousand | 473.49 Thousand | 1.17 Million |
| Selling, General and Administrative Expenses | 249.97 Thousand | 241.89 Thousand | - | 627.28 Thousand | 311.76 Thousand | 1.01 Million |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | -31.99 Thousand | - | -7481.00 | -15.32 Thousand |
| Cost and Expenses | 413.61 Thousand | 408.41 Thousand | 3.05 Million | 792.03 Thousand | 474.31 Thousand | 1.17 Million |
| Operating Income | -411.96 Thousand | -400.04 Thousand | -2.91 Million | -786.05 Thousand | -472.79 Thousand | -1.13 Million |
| Interest Expense | 309.34 Thousand | 309.34 Thousand | 1.28 Million | 374.15 Thousand | 285.89 Thousand | 312.86 Thousand |
| Income Tax Expense | 2.00 | 2.00 | -2.00 | 2.00 | 278.41 Thousand | 297.54 Thousand |
| Earnings before Tax | -721.29 Thousand | -709.37 Thousand | 6.92 Million | -1.6 Million | -766.17 Thousand | 2.06 Million |
| Net Income | -721.29 Thousand | -709.37 Thousand | 6.92 Million | -1.6 Million | -766.17 Thousand | 2.06 Million |
| Earnings Per Share Basic | -0.00 | -0.00 | - | -0.01 | -0.00 | 0.01 |
| Earnings Per Share Diluted | -0.00 | -0.00 | - | -0.01 | -0.00 | 0.01 |
| Weighted Average Shares Outstanding | 396.75 Million | 625.41 Million | 276.35 Million | 318.75 Million | 298.39 Million | 276.33 Million |
| Weighted Average Shares Outstanding (Diluted) | 396.75 Million | 625.41 Million | 1.35 Billion | 318.75 Million | 298.39 Million | 1.35 Billion |
| Gross Margin | -97.52 | -18.87 | -3.67 | -26.54 | 0.46 | -2.58 |
| EBIT Margin | -150.65 | -28.43 | - | -104.37 | -209.57 | -21.79 |
| Profit Margin | -434.25 | -84.63 | 49.38 | -268.04 | -504.06 | 45.66 |
| EBITDA | -250.23 Thousand | -238.31 Thousand | - | -624.32 Thousand | -318.55 Thousand | -984.9 Thousand |
| Earnings Before Tax Margin | -248.02 | -47.73 | -20.82 | -131.40 | -311.05 | -25.03 |
CHN
BDCM
FBGI
MULTI
SVKEF
603466